Cargando…
Buformin suppresses osteosarcoma via targeting AMPK signaling pathway
BACKGROUND: Buformin has been reported to be a powerful anticancer drug by activating the AMPK signal. Herein, we aimed to investigate the effects of buformin on osteosarcoma. MATERIAL AND METHODS: Cellular proliferative abilities were determined by cell counting kit-8 and colony formation assays. C...
Autores principales: | Ding, Yan, Lv, Shiqiao, Li, Guangrun, Cui, Jinpeng, Chen, Yunzhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874575/ https://www.ncbi.nlm.nih.gov/pubmed/33817229 http://dx.doi.org/10.1515/biol-2020-0041 |
Ejemplares similares
-
Ascorbate Plus Buformin in AML: A Metabolic Targeted Treatment
por: Banella, Cristina, et al.
Publicado: (2022) -
FXR suppresses colorectal cancer by inhibiting the Wnt/β-catenin pathway via activation of TLE3
por: Dong, Xingchen, et al.
Publicado: (2022) -
Microtubule actin crosslinking factor 1 functions as a novel therapeutic target in lung metastasis of osteosarcoma
por: Yang, Chaofei, et al.
Publicado: (2022) -
CTGF/CCN2 promotes the proliferation of human osteosarcoma cells via cross-talking with the stromal CXCL12/CXCR4-AKT-αvβ3 signaling axis in tumor microenvironment
por: Zhou, Zhangxu, et al.
Publicado: (2022) -
Relationship between Scheuermann disease and symptomatic thoracic spinal stenosis: A retrospective study
por: Ding, Yan, et al.
Publicado: (2021)